公开(公告)号：US20210301032A1

公开(公告)日：2021-09-30

申请号：US16950418

申请日：2020-11-17

申请人： Genentech, Inc.

发明人： Cecilia P.C. Chiu ,  Hilda Y. Hernandez-Barry ,  David B. Iaea ,  Moulay Hicham Alaoui-Ismaili ,  James T. Koerber ,  Wei Yu Lin ,  Kelly Loyet ,  Yonglian Sun ,  Benjamin T. Walters ,  Jawahar Sudhamsu

IPC分类号： C07K16/40 ,  A61K47/68

摘要： The invention provides anti-KLK5 antibodies and methods of using the same.

公开(公告)号：US12037412B2

公开(公告)日：2024-07-16

申请号：US16950418

申请日：2020-11-17

申请人： Genentech, Inc.

发明人： Cecilia P. C. Chiu ,  Hilda Y. Hernandez-Barry ,  David B. Iaea ,  Moulay Hicham Alaoui-Ismaili ,  James T. Koerber ,  Wei Yu Lin ,  Kelly Loyet ,  Yonglian Sun ,  Benjamin T. Walters ,  Jawahar Sudhamsu

IPC分类号： C07K16/40 ,  A61K47/68

CPC分类号： C07K16/40 ,  A61K47/6871 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention provides anti-kallikrein-related peptidase 5 (KLK5) antibodies and methods of using the same.

公开(公告)号：US20200040103A1

公开(公告)日：2020-02-06

申请号：US16352619

申请日：2019-03-13

申请人： Genentech, Inc.

发明人： Cecilia P. C. Chiu ,  Hilda Y. Hernandez-Barry ,  David B. Iaea ,  Moulay Hicham Alaoui-Ismaili ,  James T. Koerber ,  Wei Yu Lin ,  Kelly Loyet ,  Yonglian Sun ,  Benjamin T. Walters ,  Jawahar Sudhamsu

IPC分类号： C07K16/40 ,  A61K47/68

摘要： The invention provides anti-KLK5 antibodies and methods of using the same.

公开(公告)号：US20190078160A1

公开(公告)日：2019-03-14

申请号：US15958696

申请日：2018-04-20

申请人： Genentech, Inc.

发明人： Amy Dressen ,  David B. Iaea ,  Moulay Hicham Alaoui Ismaili ,  Janet K. Jackman ,  Robert A. Lazarus ,  Kelly Loyet ,  Henry R. Maun ,  Brian L. Yaspan ,  Tangsheng Yi ,  Joseph R. Arron ,  Hilda Y. Hernandez-Barry

IPC分类号： C12Q1/6883

摘要： Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Syndrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.